Physiological evidence of the hypothalamic control of pituitary growth hormone secretion has existed for many years and hypothalamic extracts from different species have been shown to stimulate growth hormone release both in vivo and in vitro. The isolation, characterisation, and synthesis of growth hormone releasing hormone has, however, taken longer to accomplish.
It has been known for some time that patients with carcinoid tumours may develop acromegaly, and the production by these tumours of biologically active substances with growth hormone releasing activity has been shown. In 1982, Thorner et 
Potential for treatment of growth hormone deficiency
The treatment of children suffering growth hormone deficiency of hypothalamic origin with synthetic releasing hormone would be more physiological than their treatment with human growth hormone. The treatment potential of growth hormone releasing hormone depends on its ability to increase and maintain plasma somatomedin concentrations and thereby induce normal linear growth. A significant increase of somatomedin C during five days of intermittent administration of growth hormone releasing hormone (1-40) has recently been reported.7
We have seen an acute rise of somatomedin C into the normal range after a single bolus infusion of releasing hormone in a child with hypopituitarism, and a maintained rise accompanying an increase iij growth hormone concentrations during releasing hormone infusion. A significant increase in height velocity in one growth hormone deficient child during a six month period of pulsatile subcutaneous releasing hormone administration has recently been reported in abstract form.
It is very likely, therefore, that growth hormone releasing hormone treatment may stimulate growth in many growth hormone deficient children.8 Human growth hormone extracted from cadaveric pituitaries is in short supply and expensive to produce. Synthetic releasing hormone or its analogues may provide a new approach to the treatment of growth hormone deficiency, thus reducing the demand for human growth hormone. The optimum dose and mode of administration of this new hypothalamic hormone is the subject of active research in a number of centres at the present time.
hormone. 
Growth hormone releasing

